BMO Capital Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to $293
BMO Capital analyst David Lebowitz maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and raises the price target from $292 to $293.
Follow the latest Alnylam Pharmaceuticals, Inc. (ALNY) news and market headlines alongside the live ALNY price. Stay informed on what's moving ALNY.

BMO Capital analyst David Lebowitz maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and raises the price target from $292 to $293.
Cramer called UiPath cheap but lacking catalysts, endorsed Karman and Affirm, warned on Onto and Nio, and favored Regeneron, Vertex and Amgen over Alnylam
The FDA approves Regeneron's Livsayis as the first siRNA therapy for adults with generalized myasthenia gravis, requiring four annual doses.
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $455 to $250.
Cantor Fitzgerald analyst Olivia Brayer Saunders maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Neutral and lowers the price target from $290 to $205.
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to ALNY, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.